NO2017034I1 - Idarucizumab - Google Patents

Idarucizumab

Info

Publication number
NO2017034I1
NO2017034I1 NO2017034C NO2017034C NO2017034I1 NO 2017034 I1 NO2017034 I1 NO 2017034I1 NO 2017034 C NO2017034 C NO 2017034C NO 2017034 C NO2017034 C NO 2017034C NO 2017034 I1 NO2017034 I1 NO 2017034I1
Authority
NO
Norway
Prior art keywords
idarucizumab
Prior art date
Application number
NO2017034C
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP10151239 priority Critical
Priority to US38391410P priority
Priority to EP11703410.8A priority patent/EP2525812B1/en
Priority to PCT/EP2011/050749 priority patent/WO2011089183A2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42061991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017034(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO2017034I1 publication Critical patent/NO2017034I1/no
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626Diabody or triabody
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
NO2017034C 2010-01-20 2017-07-11 Idarucizumab NO2017034I1 (no)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP10151239 2010-01-20
US38391410P true 2010-09-17 2010-09-17
EP11703410.8A EP2525812B1 (en) 2010-01-20 2011-01-20 Anticoagulant antidotes
PCT/EP2011/050749 WO2011089183A2 (en) 2010-01-20 2011-01-20 Anticoagulant antidotes

Publications (1)

Publication Number Publication Date
NO2017034I1 true NO2017034I1 (no) 2017-07-11

Family

ID=42061991

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2017034C NO2017034I1 (no) 2010-01-20 2017-07-11 Idarucizumab

Country Status (42)

Country Link
US (3) US8486398B2 (no)
EP (2) EP2525812B1 (no)
JP (2) JP5575923B2 (no)
KR (1) KR101781787B1 (no)
CN (1) CN102711813B (no)
AP (1) AP201206242A0 (no)
AR (1) AR079944A1 (no)
AU (1) AU2011208719C1 (no)
BR (1) BR112012018021A2 (no)
CA (1) CA2787566A1 (no)
CO (1) CO6571889A2 (no)
CY (1) CY1118875T1 (no)
DK (1) DK2525812T3 (no)
EA (1) EA028371B1 (no)
EC (1) ECSP12012105A (no)
ES (1) ES2614992T3 (no)
GE (1) GEP20156341B (no)
HK (1) HK1173957A1 (no)
HR (1) HRP20170613T1 (no)
HU (2) HUE032263T2 (no)
IL (1) IL219427A (no)
LT (2) LT2525812T (no)
LU (1) LUC00028I2 (no)
MA (1) MA33936B1 (no)
ME (1) ME02602B (no)
MX (1) MX2012008360A (no)
MY (1) MY162323A (no)
NL (1) NL300882I2 (no)
NO (1) NO2017034I1 (no)
NZ (1) NZ599508A (no)
PE (1) PE20121516A1 (no)
PL (1) PL2525812T3 (no)
PT (1) PT2525812T (no)
RS (1) RS55683B1 (no)
SG (1) SG182552A1 (no)
SI (1) SI2525812T1 (no)
TN (1) TN2012000366A1 (no)
TW (1) TWI513466B (no)
UA (1) UA110470C2 (no)
UY (1) UY33196A (no)
WO (1) WO2011089183A2 (no)
ZA (1) ZA201202876B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT
EP2663579B1 (en) 2011-01-14 2017-04-26 The Regents of the University of California Therapeutic antibodies against ror-1 protein and methods for use of same
US20140050743A1 (en) * 2011-01-19 2014-02-20 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
EA201301090A1 (ru) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Антидоты антикоагулянтов
AU2012345975B2 (en) 2011-11-29 2016-12-15 Perosphere Pharmaceuticals Inc. Anticoagulant reversal agents
TW201529602A (zh) 2013-03-14 2015-08-01 Bayer Healthcare Llc 對抗抗凝血酶β之單株抗體
EP3060583A1 (en) * 2013-10-25 2016-08-31 Boehringer Ingelheim International GmbH Anticoagulant antidotes
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
CN105223348A (zh) * 2014-05-26 2016-01-06 北京九强生物技术股份有限公司 人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
WO2016044645A1 (en) * 2014-09-17 2016-03-24 Elmaleh David R Anticoagulant derivatives for cardiovascular imaging
WO2019217705A1 (en) * 2018-05-11 2019-11-14 Proplex Technologies, LLC Binding proteins and chimeric antigen receptor t cells targeting gasp-1 granules and uses thereof
WO2020180489A1 (en) 2019-03-06 2020-09-10 University Of Rochester Anticoagulant compositions and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
DE68913658T3 (de) 1988-11-11 2005-07-21 Medical Research Council Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU676150B2 (en) * 1992-01-23 1997-03-06 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
ES2108460T3 (es) 1993-06-03 1997-12-16 Therapeutic Antibodies Inc Fragmentos de anticuerpos en terapeutica.
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
AU7266898A (en) 1997-04-30 1998-11-24 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
DE19729544A1 (de) * 1997-07-10 1999-01-14 Basf Ag Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
ES2484966T3 (es) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US20070031438A1 (en) * 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
EP2316951A1 (en) 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
EP2193196B1 (en) 2007-09-28 2016-07-13 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
AR077909A1 (es) 2009-08-24 2011-09-28 Boehringer Ingelheim Int Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT

Also Published As

Publication number Publication date
HUS1700030I1 (hu) 2017-08-28
AU2011208719A1 (en) 2012-05-17
AU2011208719C1 (en) 2017-07-13
TW201136606A (en) 2011-11-01
ME02602B (me) 2017-06-20
WO2011089183A3 (en) 2011-11-17
DK2525812T3 (en) 2017-02-27
UA110470C2 (ru) 2016-01-12
LUC00028I1 (no) 2017-07-14
LTC2525812I2 (lt) 2019-05-10
US9034822B2 (en) 2015-05-19
LTPA2017021I1 (lt) 2017-07-25
UY33196A (es) 2011-08-31
KR101781787B1 (ko) 2017-09-26
TWI513466B (zh) 2015-12-21
EP3195876A1 (en) 2017-07-26
EP2525812A2 (en) 2012-11-28
US20130289248A1 (en) 2013-10-31
RS55683B1 (sr) 2017-07-31
SG182552A1 (en) 2012-08-30
HK1173957A1 (zh) 2013-05-31
IL219427D0 (en) 2012-06-28
PT2525812T (pt) 2017-04-26
IL219427A (en) 2018-05-31
CY1118875T1 (el) 2018-01-10
JP2013517317A (ja) 2013-05-16
US20120027780A1 (en) 2012-02-02
EA201201016A1 (ru) 2013-02-28
ECSP12012105A (es) 2012-10-30
KR20120128126A (ko) 2012-11-26
NZ599508A (en) 2014-05-30
EP2525812B1 (en) 2017-01-18
MX2012008360A (es) 2012-08-08
HUE032263T2 (en) 2017-09-28
BR112012018021A2 (pt) 2017-06-20
TN2012000366A1 (en) 2014-01-30
CN102711813A (zh) 2012-10-03
SI2525812T1 (sl) 2017-05-31
US8486398B2 (en) 2013-07-16
GEP20156341B (en) 2015-08-10
JP5575923B2 (ja) 2014-08-20
JP2014210794A (ja) 2014-11-13
LT2525812T (lt) 2017-02-27
LUC00028I2 (no) 2017-09-25
PE20121516A1 (es) 2012-11-24
MY162323A (en) 2017-05-31
WO2011089183A2 (en) 2011-07-28
CN102711813B (zh) 2015-03-04
ZA201202876B (en) 2012-12-27
MA33936B1 (fr) 2013-01-02
HRP20170613T1 (hr) 2017-06-30
US20150210778A1 (en) 2015-07-30
CA2787566A1 (en) 2011-07-28
ES2614992T3 (es) 2017-06-02
AR079944A1 (es) 2012-02-29
PL2525812T3 (pl) 2017-07-31
CO6571889A2 (es) 2012-11-30
NL300882I2 (nl) 2017-07-20
EA028371B1 (ru) 2017-11-30
AP201206242A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
NO2019034I1 (no) lorlatinib
NO2017023I2 (no) Venetoklaks
NO2016004I2 (no) Ledipasvir
NO2019007I1 (no) Tisagenlekleucel
NO2019020I1 (no) lanadelumab
NO2020017I1 (no) Siponimod
NO2019022I1 (no) Natriumzirkoniumsyklosilikat
SMT201600400B (it) Inalatore
NO2019038I1 (no) Risankizumab
CO6811812A2 (es) Anticuerpo anti-b7-h3
NO2018039I1 (no) Rukaparibkamsylat
ITVI20100321A1 (it) Bottiglia
NO20140526A1 (no) Svanehals-ledningssystem
NO2017034I1 (no) Idarucizumab
CR20130111A (es) Triazina-oxidiazoles
NO20131470A1 (no) Bropluggverktøy
NO20120395A1 (no) Stromningsstyringssystem
NO2010019I2 (no) 6-per-deoxy-6-per- (2-karboksetyl) thio-y-cyclodextrin
CO6801726A2 (es) Compuestos
CO6960543A2 (es) 2-thiopyrimidinones
SMT201500078B (it) Fellosilicato modificato
NO20100814A1 (no) Tynnkompositter
NO340857B1 (no) Tykkvegget komposittrør
NO20110970A1 (no) Oppbygget flenslasedeksel
NO20111616A1 (no) Trykkskjot